Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics

Launched by THE FIRST AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY · Jan 20, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to better understand severe acute pancreatitis, a serious condition where the pancreas becomes inflamed. Researchers will study samples from 30 healthy individuals and 146 patients with varying degrees of pancreatitis—mild, moderate, and severe. The main goal is to explore how changes in gut bacteria and blood composition relate to the severity of the disease. This could help identify early warning signs and biomarkers, which are substances that can indicate the presence or severity of a disease.

To participate, patients should be between 18 and 75 years old and must have experienced acute pancreatitis within the last 72 hours. Healthy volunteers should also be in the same age range but must not have had any history of acute pancreatitis and should be in good health based on routine lab tests. Participants will provide blood and stool samples, and while the study is not currently recruiting, it aims to gather important information that could improve future treatments for acute pancreatitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients group:
• • ① Age between 18 and 75 years old;
• • ② Within 72 hours of AP onset;
• • ③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.
• Healthy control group:
• • Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.
• Exclusion Criteria:
• • Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;
• • Pregnant and lactating women;
• • Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;
• • Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.